AU2018286649B2 - Method for reducing lung inflammation - Google Patents

Method for reducing lung inflammation Download PDF

Info

Publication number
AU2018286649B2
AU2018286649B2 AU2018286649A AU2018286649A AU2018286649B2 AU 2018286649 B2 AU2018286649 B2 AU 2018286649B2 AU 2018286649 A AU2018286649 A AU 2018286649A AU 2018286649 A AU2018286649 A AU 2018286649A AU 2018286649 B2 AU2018286649 B2 AU 2018286649B2
Authority
AU
Australia
Prior art keywords
chelating agent
dose
day
inflammation
lung
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018286649A
Other languages
English (en)
Other versions
AU2018286649A1 (en
Inventor
Barry Clements
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Respirion Pharmaceuticals Pty Ltd
Original Assignee
Respirion Pharmaceuticals Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017902365A external-priority patent/AU2017902365A0/en
Application filed by Respirion Pharmaceuticals Pty Ltd filed Critical Respirion Pharmaceuticals Pty Ltd
Publication of AU2018286649A1 publication Critical patent/AU2018286649A1/en
Application granted granted Critical
Publication of AU2018286649B2 publication Critical patent/AU2018286649B2/en
Priority to AU2023270302A priority Critical patent/AU2023270302B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2018286649A 2017-06-20 2018-06-20 Method for reducing lung inflammation Active AU2018286649B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2023270302A AU2023270302B2 (en) 2017-06-20 2023-11-23 Method for Reducing Lung Inflammation

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2017902365 2017-06-20
AU2017902365A AU2017902365A0 (en) 2017-06-20 Method For Reducing Lung Inflammation
PCT/AU2018/050609 WO2018232452A1 (en) 2017-06-20 2018-06-20 METHOD FOR REDUCING PULMONARY INFLAMMATION

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023270302A Division AU2023270302B2 (en) 2017-06-20 2023-11-23 Method for Reducing Lung Inflammation

Publications (2)

Publication Number Publication Date
AU2018286649A1 AU2018286649A1 (en) 2019-12-05
AU2018286649B2 true AU2018286649B2 (en) 2023-11-09

Family

ID=64735378

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018286649A Active AU2018286649B2 (en) 2017-06-20 2018-06-20 Method for reducing lung inflammation
AU2023270302A Active AU2023270302B2 (en) 2017-06-20 2023-11-23 Method for Reducing Lung Inflammation

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2023270302A Active AU2023270302B2 (en) 2017-06-20 2023-11-23 Method for Reducing Lung Inflammation

Country Status (8)

Country Link
US (2) US11491126B2 (https=)
EP (1) EP3641749A4 (https=)
JP (3) JP7729713B2 (https=)
CN (1) CN111050762A (https=)
AU (2) AU2018286649B2 (https=)
BR (1) BR112019027257A2 (https=)
CA (1) CA3067857A1 (https=)
WO (1) WO2018232452A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI818601B (zh) * 2021-10-29 2023-10-11 原創生醫股份有限公司 用於上呼吸道給藥之組成物及其用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008137747A1 (en) * 2007-05-02 2008-11-13 The Regents Of The University Of Michigan Nanoemulsion therapeutic compositions and methods of using the same
US20160263151A1 (en) * 2015-03-11 2016-09-15 University Of Cincinnati Compositions and methods for treating bacterial infection
WO2017096013A1 (en) * 2015-12-01 2017-06-08 Cornell University Use of mitochondrial iron chelators for treatment of chronic obstructive pulmonary disease

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5497763A (en) 1993-05-21 1996-03-12 Aradigm Corporation Disposable package for intrapulmonary delivery of aerosolized formulations

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008137747A1 (en) * 2007-05-02 2008-11-13 The Regents Of The University Of Michigan Nanoemulsion therapeutic compositions and methods of using the same
US20160263151A1 (en) * 2015-03-11 2016-09-15 University Of Cincinnati Compositions and methods for treating bacterial infection
WO2017096013A1 (en) * 2015-12-01 2017-06-08 Cornell University Use of mitochondrial iron chelators for treatment of chronic obstructive pulmonary disease

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
AOKI ET AL.: "Efficacy of Calcium-EDTA as an Inhibitor for Metallo-p-Lactamase in a Mouse Model of Pseudomonas aeruginosa Pneumonia", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 54, no. 11, 2010, pages 4582 - 4588, XP055560937 *
HILLMAN ET AL.: "Aerosol EDTA to eliminate respiratory-tract Pseudomonas", THE LANCET, vol. 2, no. 8394, 1984, pages 99, XP055560934 *
KUMAR ET AL.: "Edetate calcium disodium nanoparticle dry powder inhalation: A novel approach against heavy metal decorporation", INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 416, no. 1, 2011, pages 376 - 383, XP028264550 *
PETROVIC ET AL.: "Aerosol Inhalation of CaNa2E.D.T.A. (MOSATIL) by Workers Constantly Exposed to Lead Poisoning", BRITISH JOURNAL OF INDUSTRIAL MEDICINE, vol. 17, 1960, pages 201 - 204, XP055560942 *
ZAROGIANNIS ET AL.: "Ascorbate and Deferoxamine Administration after Chlorine Exposure Decrease Mortality and Lung Injury in Mice", AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, vol. 45, no. 2, 2011, pages 386 - 392 *

Also Published As

Publication number Publication date
AU2023270302A1 (en) 2023-12-14
EP3641749A4 (en) 2021-03-17
AU2023270302B2 (en) 2025-10-23
US20200163920A1 (en) 2020-05-28
CA3067857A1 (en) 2018-12-27
JP2025098035A (ja) 2025-07-01
JP2020524173A (ja) 2020-08-13
BR112019027257A2 (pt) 2020-07-14
JP2023071952A (ja) 2023-05-23
JP7729713B2 (ja) 2025-08-26
WO2018232452A1 (en) 2018-12-27
JP7848150B2 (ja) 2026-04-20
AU2018286649A1 (en) 2019-12-05
US11491126B2 (en) 2022-11-08
EP3641749A1 (en) 2020-04-29
US20230045633A1 (en) 2023-02-09
CN111050762A (zh) 2020-04-21

Similar Documents

Publication Publication Date Title
Kim et al. Polyhexamethylene guanidine phosphate aerosol particles induce pulmonary inflammatory and fibrotic responses
Sermet-Gaudelus et al. Nebulized antibiotics in cystic fibrosis
AU2023285900B2 (en) Method For Reducing Lung Infection
KR101735123B1 (ko) 리포솜 아미카신 제형물로의 폐 장애 치료 방법
NZ564110A (en) Formulations for alteration of biophysical properties of mucosal lining
Stockmann et al. Clinical pharmacokinetics of inhaled antimicrobials
JP2025098035A (ja) 肺炎症を低減させる方法
Krishna et al. Liposomal drug delivery to the lungs: a post covid-19 scenario
Sheikh et al. Is there a role for inhaled anti-inflammatory drugs in cystic fibrosis treatment?
TW201138785A (en) Inhaled fosfomycin/tobramycin for the treatment of chronic obstructive pulmonary disease
US7012091B1 (en) Inhalable inhibitors of inflammation in the respiratory tract
Toso et al. Inhaled antibiotics in cystic fibrosis: a review
Hasan et al. Estimating in vivo airway surface liquid concentration in trials of inhaled antibiotics
AU2011227613B2 (en) Aerosolized dapsone as a therapy for inflammation of the airway and abnormal mucociliary transport
BR122025016291A2 (pt) Uso do agente quelante ácido etilenodiamino tetra-acético (edta) na fabricação de uma formulação inalável, formulação inalável e kit para tratar ou prevenir inflamação no pulmão
Narasimhan et al. New and investigational treatments in cystic fibrosis
US20170020838A1 (en) Treatment for respiratory disease
US7015244B1 (en) Inhalable chemical debridement for COPD
Bensman Therapeutic Potential of Rhesus Theta (θ) Defensin-1 in Cystic Fibrosis Airway Infection and Inflammation
Oguejiofor Investigating the delivery of antimicrobial proteins and aminoglycoside antibiotics to the airways

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)